NOI to Sole Source AMICUS Apheresis Reagents & Consumables
Closed Pre-Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- HT941026N0107
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- Place of performance
- United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Health Agency Contracting Activity, Healthcare Contracting Division – West, intends to award a sole-source firm-fixed-price purchase order to Fenwal, Inc. for drop shipment of FDA Amicus Apheresis reagents and consumables, with capability challenge submissions due by 1000 Pacific Daylight Time, Friday, August 28, 2026.
The procurement supports Naval Hospital Okinawa, Japan (Bldg 960, Tarawa Road, Camp Foster), and covers Intercept platelet small volume processing sets and platelet dual storage containers used in pathogen reduction of donated blood platelets. Performance of delivery runs October 1, 2026, through September 30, 2027, with drop shipment to MAB, DLA Troop Support Xdock West Project at Cardinal Health MPS Distribution Center, 4551 East Philadelphia Street, Ontario, California.
Fenwal, Inc. (UEI: E9UHXHZCGJV5, CAGE: 4Q7Q2, located at 3 Corporate Drive Suite 300, Lake Zurich, Illinois) is identified as the sole manufacturer capable of meeting minimum requirements. The Contracting Officer does not have a reasonable expectation that two or more offers will be received, justifying the sole-source award under FAR 12.102(a).
NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing, 1,250-employee business size standard) and PSC code 6550 (In-Vitro Diagnostic Substances, Reagents, Test Kits and Sets) apply. The items are FDA-mandated for pathogen reduction processing at the Naval Hospital Okinawa PACOM Armed Services Blood Bank Center.
Interested vendors may challenge the sole-source basis by submitting capability statements (maximum four pages, 8.5" × 11", 10-point font minimum) with management, technical, and cost data to Mariangela Monsalve (mariangela.j.monsalve.civ@health.mil) or Bobbie Dobberstein (bobbie.s.dobberstein.ctr@health.mil). The Government reserves discretion to conduct competitive procurement based on responses received.
Notice text
Notice of Intent to Sole Source HT941026N0107
THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES.
The Defense Health Agency Contracting Activity (DHACA), Healthcare Contracting Division – West (HCD-W), intends to award a firm-fixed-price purchase order for Drop Shipment of FDA Fenwal Amicus Apheresis Reagents (Manufacturer: Fenwal, Inc.). This procurement supports the operational requirements of Naval Hospital Okinawa, Japan, and is conducted in accordance with Federal Acquisition Regulation (FAR) 12.102(a), this acquisition of commercial products and services is being executed as a sole source, as the Contracting Officer does not have a reasonable expectation that two or more offers will be received.
FENWAL, INC., 3 CORPORATE DR STE 300, LAKE ZURICH, IL 60047-8930, United States
UEI: E9UHXHZCGJV5
CAGE: 4Q7Q2
The North American Industry Classification System (NAICS) code for this requirement is 325413, In-Vitro Diagnostic Substance Manufacturing, which has a business size standard of 1,250 employees. The product service code (PSC) is 6550, In-Vitro Diagnostic Substances, Reagents, Test Kits and Sets.
The objective of this sole source award is to procure Amicus Apheresis reagents for the cell separator for Naval Hospital Okinawa, located at Bldg 960, Tarawa Road, Camp Foster, Okinawa, Japan.
The requested Intecept platelet small volume processing set and platelet dual storage containers are used in the Intercept pathogen reducing equipment. These items are vital in the collection, treatment and sustainment of adequate inventory of blood platelets products for routine and emergent patient care and mission requirement. Pathogen reduction of donated blood platelet products reduces the transmission of viruses and infections upon transfusion. US Naval Hospital Okinawa PACOM Armed Services Blood Bank Center (ASBBC) is mandated by FDA to conduct pathogen reduction process for all collected blood platelets. Supplies of the platelet sets are historically sustained thru a drop shipment contract. The suggested vendor is the sole manufacturer and provider of the platelet sets.
Fenwal, Inc., is the only source capable of meeting the government’s minimum requirements.
Delivery Period: 1 October 2026 through 30 September 2027
Delivery Location: MAB, DLA TROOP SUPPORT XDOCK WEST PROJECT, C/O CARDINAL HEALTH MPS DISTRIBUTION CENTER, 4551 EAST PHILADELPHIA STREET, ONTARIO CA 91761
This notice of intent is not a request for competitive proposals, and no formal solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement. Submissions must include management, technical, and cost data in sufficient detail accompanied by convincing evidence to clearly demonstrate the capability to provide the required equipment and preventive maintenance. Capability statements shall not exceed four (4) pages (8.5" x 11" format) using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. Requests for documentation, inquiries for additional information, or submissions consisting solely of questions will not be considered affirmative responses. A determination by the Government not to compete this requirement based on responses to this notice is solely within the discretion of the Government. Information received will be considered exclusively for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole-source purchase order.
Response Instructions: If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to:
- Mariangela Monsalve at mariangela.j.monsalve.civ@health.mil
- Bobbie Dobberstein at bobbie.s.dobberstein.ctr@health.mil
The closing date for challenges is no later than 1000 Pacific Daylight Time, Friday, August 28, 2026.
NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED.
Files
| File | Type | Posted |
|---|---|---|
| HT941026N0107 NOI NHO AMICUS Cell Separator Sys Consumables.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| NHO Amicus Stem Cell Separator System Consumables | Award Notice | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| BPA - Consumable Supplies for Terumo Trima Accel Blood Collection systems | Defense Health Agency | Service-Disabled Veteran-Owned Small Business | |
| Intent to Sole Source - Medical/Scientific Instruments for the Department of Transfusion Medicine, NIH Clinical Center | National Institutes of Health | No set-aside | |
| Reagents and consumables for Roche immunostainers | Office of Logisitics and Acquisition Operations | No set-aside | |
| 6505--Human Blood and Blood Products | Veterans Integrated Service Network 17 | No set-aside | |
| 6550--hemochron signature elite reagents and supplies | Veterans Integrated Service Network 22 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity